The dual-marker approach involving ANKRD22 and SERPING1 shows promising clinical utility as a potential predictor of tuberculosis drug resistance, offering novel perspectives for improving diagnostic timelines and treatment strategies in drug-resistant TB management. The gene discussed is ANKRD22; the disease is tuberculosis.